esophageal carcinoma (Cancer)
Information
- Disease name
- esophageal carcinoma
- Disease ID
- DOID:1107
- Description
- "A esophageal cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells." [url:http\://en.wikipedia.org/wiki/Esophageal_cancer]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| SBF2 | 11 | 9,778,844 | 10,294,128 | 136 |
| TP53 | 17 | 7,668,421 | 7,687,490 | 10 |
| ANK3 | 10 | 60,026,298 | 60,389,875 | 6 |
| TMEM14A | 6 | 52,671,113 | 52,686,588 | 6 |
| TEAD1 | 11 | 12,674,421 | 12,944,737 | 4 |
| NFE2L2 | 2 | 177,230,308 | 177,264,727 | 4 |
| EVX2 | 2 | 176,077,472 | 176,083,962 | 2 |
| CCND1 | 11 | 69,641,156 | 69,654,474 | 2 |
| FGFR2 | 10 | 121,478,332 | 121,598,444 | 2 |
| LTO1 | 11 | 69,665,563 | 69,675,353 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT03110926 | Active, not recruiting | Phase 2 | Induction Chemotherapy for Locally Advanced Esophageal Cancer | June 19, 2017 | June 12, 2024 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT04505553 | Active, not recruiting | Phase 2 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | June 1, 2021 | September 30, 2024 |
| NCT04607590 | Active, not recruiting | Yoga Program for Improving the Quality of Life in Couples Coping With Cancer | May 31, 2019 | April 30, 2025 | |
| NCT01262040 | Completed | N/A | Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | December 14, 2010 | October 29, 2018 |
| NCT01544790 | Completed | Phase 3 | Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy | April 2012 | August 2016 |
| NCT01691625 | Completed | N/A | Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer | September 2012 | December 2021 |
| NCT01766986 | Completed | Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction | January 2008 | January 2013 | |
| NCT01855854 | Completed | Phase 2 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | May 2013 | January 7, 2016 |
| NCT00176800 | Completed | Phase 2 | Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma | November 2001 | May 2013 |
| NCT00423254 | Completed | Phase 1 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | February 2007 | November 2009 |
| NCT00590031 | Completed | Phase 2 | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | November 2002 | December 2009 |
| NCT00733889 | Completed | Phase 2 | A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma | December 2006 | November 2012 |
| NCT01097304 | Completed | Phase 2 | Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia | April 2010 | July 2014 |
| NCT02120911 | Completed | Phase 1/Phase 2 | Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma | January 2014 | February 2017 |
| NCT02559687 | Completed | Phase 2 | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | December 2, 2015 | October 29, 2021 |
| NCT02564263 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | December 1, 2015 | March 14, 2022 |
| NCT02861690 | Completed | Phase 2 | Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma | January 2010 | January 2016 |
| NCT02965976 | Completed | Phase 2 | Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer | December 30, 2016 | April 28, 2022 |
| NCT03099382 | Completed | Phase 3 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | May 5, 2017 | May 6, 2019 |
| NCT03933449 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | December 29, 2016 | March 14, 2022 |
| NCT06048913 | Enrolling by invitation | Phase 1 | Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | July 1, 2022 | July 1, 2028 |
| NCT06067438 | Not yet recruiting | Phase 2 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | May 1, 2024 | August 30, 2025 |
| NCT05937438 | Not yet recruiting | Phase 1/Phase 2 | Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | September 1, 2023 | December 31, 2026 |
| NCT05996484 | Not yet recruiting | Phase 2 | Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | September 2023 | July 2026 |
| NCT03094351 | Recruiting | Phase 3 | Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy | July 29, 2017 | December 1, 2024 |
| NCT06265285 | Recruiting | Phase 2 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | March 13, 2024 | December 31, 2026 |
| NCT00991094 | Recruiting | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | May 27, 2005 | December 31, 2025 | |
| NCT04652180 | Recruiting | N/A | Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy . | November 6, 2020 | December 30, 2026 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05476380 | Recruiting | Phase 2 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | February 19, 2021 | December 1, 2024 |
| NCT05775939 | Recruiting | N/A | PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial | January 20, 2023 | January 1, 2026 |
| NCT05777707 | Recruiting | Phase 1/Phase 2 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | October 29, 2020 | December 31, 2024 |
| NCT05780736 | Recruiting | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer | August 4, 2023 | September 30, 2028 | |
| NCT05795595 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | March 13, 2023 | May 2030 |
| NCT05952661 | Recruiting | Minimally Residual of Esophageal Cancer 001 | February 22, 2023 | December 31, 2027 | |
| NCT06199895 | Recruiting | Phase 2 | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer | November 28, 2023 | November 2025 |
| NCT06009705 | Recruiting | Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer | October 1, 2022 | April 30, 2026 | |
| NCT06231680 | Recruiting | Phase 2 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | January 19, 2024 | September 30, 2025 |
| NCT06354218 | Recruiting | Phase 2 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | December 1, 2023 | December 1, 2027 |
| NCT03948100 | Recruiting | N/A | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | December 20, 2018 | April 30, 2025 |
| NCT04147494 | Recruiting | Early Phase 1 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | November 5, 2019 | October 17, 2031 |
| NCT04517019 | Recruiting | N/A | Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy | August 1, 2020 | August 1, 2025 |
| NCT02062632 | Terminated | Phase 2 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | April 14, 2014 | November 6, 2017 |
| NCT03381651 | Unknown status | N/A | Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma | February 22, 2018 | February 22, 2023 |
| NCT03507998 | Unknown status | Phase 1 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | June 17, 2017 | April 1, 2021 |
| NCT02355249 | Unknown status | Phase 3 | Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer | September 2014 | January 2018 |
| NCT01034683 | Unknown status | Phase 3 | Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma | December 2009 | December 2010 |
| NCT01937208 | Unknown status | Phase 3 | Comparable Study of Different Radiation Dose in Esophageal Carcinoma | August 2013 | July 2017 |
| NCT00642239 | Unknown status | Phase 4 | A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma | April 2008 | December 2009 |
| NCT02527057 | Unknown status | Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer | October 2014 | December 2019 | |
| NCT03013712 | Unknown status | Phase 1/Phase 2 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer | January 2017 | December 2020 |
| NCT03220009 | Withdrawn | Phase 2 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | November 3, 2017 | July 1, 2021 |
| NCT00636298 | Withdrawn | Phase 2 | Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy | October 2008 | March 2012 |
- Disase is a (Disease Ontology)
- DOID:5041
- Cross Reference ID (Disease Ontology)
- EFO:0002916
- Cross Reference ID (Disease Ontology)
- NCI:C3513
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:255079005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0152018
- Exact Synonym (Disease Ontology)
- cancer of esophagus
- Exact Synonym (Disease Ontology)
- cancer of oesophagus
- Exact Synonym (Disease Ontology)
- carcinoma of esophagus
- Exact Synonym (Disease Ontology)
- carcinoma of oesophagus
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0011459